Highlights Topline data from Clarity's diagnostic Phase II trial, SABRE, showed that 64Cu-SAR-Bombesin was safe, well tolerated and effective at detecting prostate cancer in patients with biochemical recurrence (BCR) who are negative or equivocal on standard-of-care (SOC) scans, including prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET). SAR-Bombesin targets the gastrin-releasing peptide receptor (GRPR), a promising pan-cancer target expressed in a number of indicat

Strategic collaboration aims to validate NutriSelect's AI supplement engine through clinical trials and biomarker-based performance optimization. This is more than a business collaboration — it’s a convergence of science, spirit, and human potential.” — Dr. Bill Clark CLEARWATER, FL, UNITED STATES, June 13, 2025 / EINPresswire.com / -- NutriSelect , the visionary AI-powered platform founded by scientist and innovator Dr. Bill Clark, has signed a Letter of Intent (LOI) with The Center for Applied

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard ® Prime EPS. CGuard ® Prime was developed incorporating extensive user feedback and optimizes deliverability and deployment of the proven CGuard stent. With its proprietary MicroNet™ mesh, CGuard is designed to reduce

CAMBRIDGE, Mass., June 13, 2025 /PRNewswire/ -- Regor Therapeutics Group ("Regor"), a global innovator of clinical-stage biotechnology, today announced that it will present results from its Phase 2a trial of RGT-075 in adults with obesity or overweight with weight-related comorbidities at the 85th Scientific Sessions of American Diabetes Association (ADA) taking place June 20-23 in Chicago. Poster Presentation details are as follows: Presentation Title: First Report on the Small Molecule Oral GL

The Making of a Heart Attack Educates Viewers About High LDL-C— a Major, but Modifiable, Risk Factor for Heart Attack and Stroke THOUSAND OAKS, Calif., June 13, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of The Making of a Heart Attack, a documentary that sheds light on the cardiovascular disease crisis in the United States, where every 40 seconds someone has a heart attack or stroke.1 Experience the full interactive Multichannel News Release here: Continue Reading Fo

IRVINE, CA, UNITED STATES, June 13, 2025 / EINPresswire.com / -- Dr. Gordon McLaren, a distinguished expert in iron metabolism disorders with an extensive background in hematology and oncology, is making significant strides in his specialized field. With groundbreaking contributions to the scientific community’s understanding and management of iron disorders, particularly hereditary hemochromatosis, Dr. McLaren continues to influence both clinical practice and research. Expertise in Hematology a

SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors. “We are very pleased to welcome David to the Board of Directors. David is an experienced senior executive with global connections an

Indian startup brings pregnancy AI solutions to rural Vietnam, Laos Women's health startup Doto Health from India has entered into a strategic partnership to expand across Southeast Asia. It signed a memorandum of understanding with human development organisation FHI 360, Alive & Thrive, which is a global program focused on mother, child, and youth nutrition, and the Health Departments of Quang Tri in Vietnam and Savannakhet and Salavan in Laos to promote the adoption of digital health solutions

High-purity psilocybin export validated by rigorous laboratory testing, advancing global clinical studies on the therapeutic potential of psychedelic compounds. RUNAWAY BAY, Jamaica, June 13, 2025 (GLOBE NEWSWIRE) -- Rose Hill Apothecary (“The Company” or “Rose Hill”), a global leader in the research and intellectual property of premium psilocybin products, today announced the successful execution of its first major international export agreement, marking a significant milestone in the global

Showcased 7 presentations at ISSCR 2025, including a featured oral presentation on first-in-human gene therapy for heart failure, powered by their proprietary human mini-Heart technology. FDA-backed human-based screening platform recognized as an animal-free alternative in drug development, supporting IND and Fast Track approvals under the FDA Modernization Act 2.0. Breakthroughs in high-throughput screening, AI-driven drug classification, and patient-specific disease modelling underscored the p